Technical Analysis for AYTU - Aytu BioScience, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 5.385 | 3.16% | 0.17 |
Earnings due: May 17
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical AYTU trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 3.16% | |
| Lower Bollinger Band Walk | Weakness | 3.16% | |
| Earnings Movers | Other | 3.16% | |
| Outside Day | Range Expansion | 3.16% | |
| Wide Bands | Range Expansion | 3.16% | |
| Oversold Stochastic | Weakness | 3.16% | |
| New 52 Week Closing Low | Bearish | 1.51% | |
| Lower Bollinger Band Walk | Weakness | 1.51% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Trending on StockTwits | 2 days ago |
| Up 3% | 3 days ago |
| 60 Minute Opening Range Breakout | 3 days ago |
| Up 2% | 3 days ago |
| Up 1% | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/17/2021
Aytu BioScience, Inc. Description
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Prostate Cancer Urology In Vitro Alcohols Hormones Fertility Ketones Testosterone Imaging Agent Infertility Urinary Tract Infection Urinary Tract Infections Company's Pipeline In Vitro Diagnostic Device Male Infertility Androstanes Hypogonadism
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.0 |
| 52 Week Low | 5.1 |
| Average Volume | 690,213 |
| 200-Day Moving Average | 9.07 |
| 50-Day Moving Average | 7.19 |
| 20-Day Moving Average | 6.19 |
| 10-Day Moving Average | 5.66 |
| Average True Range | 0.39 |
| ADX | 22.05 |
| +DI | 10.84 |
| -DI | 29.22 |
| Chandelier Exit (Long, 3 ATRs ) | 6.04 |
| Chandelier Exit (Short, 3 ATRs ) | 6.26 |
| Upper Bollinger Band | 7.37 |
| Lower Bollinger Band | 5.00 |
| Percent B (%b) | 0.16 |
| BandWidth | 38.39 |
| MACD Line | -0.51 |
| MACD Signal Line | -0.45 |
| MACD Histogram | -0.066 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.85 | ||||
| Resistance 3 (R3) | 5.82 | 5.64 | 5.77 | ||
| Resistance 2 (R2) | 5.64 | 5.52 | 5.66 | 5.75 | |
| Resistance 1 (R1) | 5.51 | 5.45 | 5.58 | 5.54 | 5.72 |
| Pivot Point | 5.33 | 5.33 | 5.36 | 5.35 | 5.33 |
| Support 1 (S1) | 5.20 | 5.21 | 5.27 | 5.23 | 5.05 |
| Support 2 (S2) | 5.02 | 5.14 | 5.04 | 5.02 | |
| Support 3 (S3) | 4.89 | 5.02 | 5.00 | ||
| Support 4 (S4) | 4.92 |
